# PCOS Gets a New Name: Metabolic Disorder, Not Just Ovarian
Medical organizations have renamed polycystic ovary syndrome to polycystic metabolic syndrome, or PMOS. The change reflects a fundamental shift in how doctors understand and treat the condition affecting millions of women worldwide.
The old name created a misleading focus on ovarian cysts, when the condition actually stems from metabolic dysfunction. Women with PMOS experience insulin resistance, hormonal imbalance, and inflammation throughout their body. Not all patients even develop cysts. The misnomer delayed diagnosis and treatment for many people.
Renaming the disorder addresses several clinical problems. First, it stops doctors from dismissing symptoms in patients without visible cysts on ultrasound. Second, it emphasizes metabolic roots, guiding treatment toward insulin management and weight regulation rather than reproductive concerns alone. Third, it validates the systemic nature of the condition, which increases risk for type 2 diabetes, heart disease, and fatty liver disease.
The terminology shift comes after years of advocacy from patient groups and researchers who documented how the old name harmed care. Women reported being told they had nothing wrong because their ovaries looked normal. Others received fertility-focused treatment when they needed metabolic intervention. Internists and cardiologists often missed PMOS entirely because the condition wore an OB-GYN label.
Healthcare providers now recognize PMOS affects approximately 1 in 10 women of reproductive age, though rates vary by ethnicity and diagnostic criteria used. Symptoms include irregular periods, excess hair growth, acne, weight gain, and fatigue. Many patients also struggle with mood disorders and sleep problems tied to hormonal disruption.
Shifting from "syndrome" to "disorder" also matters linguistically. A syndrome describes a cluster of symptoms without clear cause. A disorder points to underlying pathology requiring